SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): February 5, 2013
(Exact name of Registrant as Specified in its Charter)
(State Or Other Jurisdiction Of Incorporation)
Registrant’s Telephone Number, Including Area Code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Items under Sections 1 and 3 through 8 are not applicable and therefore omitted.
Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on February 5, 2013 disclosing material non-public information regarding its results of operations for the second quarter of fiscal year 2013 ended December 31, 2012. Also furnished with this Form 8-K as Exhibit 99.2 are certain remarks of Brian J. Smrdel, the Company’s Chief Financial Officer, made at a related telephone conference held on February 5, 2013.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Date: February 6, 2013